mil62
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Feb 24, 2022 (NCT05398653)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05862233 | Phase 3 | Jun 2, 2023 | Beijing Mabworks Biotech Co., Ltd. |
| NCT05796206 | Phase 2/Phase 3 (Phase 3) | May 26, 2023 | Beijing Mabworks Biotech Co., Ltd. |
| NCT05314010 | Phase 3 | Aug 18, 2022 | Beijing Mabworks Biotech Co., Ltd. |
| NCT05398653 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2022 | Beijing Mabworks Biotech Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Mabworks Biotech Co., Ltd. | For profit | 4 | 4 | 2 | 2022 |
1 organizations
Page 1 / 1